Eyepoint Pharmaceuticals Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.0% | -93.9% | +365.4% | -22.3% | +247.8% | +69.1% | +7.3% | +12.1% | +11.1% | -6.0% | -27.5% | |
| – | +19.0% | +3.5% | +8.7% | +14.4% | -85.5% | +116.7% | +40.4% | +1.8% | -44.4% | -19.9% | -44.3% | |
| – | +83.5% | -93.9% | +365.4% | -284.8% | – | +61.9% | +0.5% | +15.0% | +25.1% | -4.4% | -25.9% | |
| – | +26.3% | +19.0% | +3.5% | +39.9% | -26.2% | +13.4% | +63.6% | +74.2% | +30.3% | +105.6% | +66.3% | |
| – | +7.9% | +11.9% | +24.7% | +37.1% | +16.5% | +15.5% | +23.4% | +36.1% | +15.2% | +30.6% | -1.4% | |
| – | +150.0% | +16.1% | +11.6% | +100.4% | +25.3% | +0.6% | +27.5% | +57.9% | -12.3% | +59.2% | +47.1% | |
| – | +0.0% | -439.1% | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | – | – | +0.0% | +757.8% | +17.5% | -24.2% | -42.0% | -60.9% | -98.9% | +135.7% | |
| – | +0.0% | -436.8% | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -261.5% | – | – | – | +17.5% | -24.2% | +304.8% | -99.6% | +8.4% | +210.0% | |
| – | +0.0% | -439.5% | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | -385.7% | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.